NCT02593227View on ClinicalTrials.gov

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Low dose FRα vaccine

165ug per peptide ID injection

DRUG

Cyclophosphamide

IV infusion over 1 hour

BIOLOGICAL

High dose FRα vaccine

500ug per peptide ID injection

Trial Locations (11)

10029

Mount Sinai Hospital, New York

10461

Montefiore Medical Center, Einstein Cancer Center, New York

21201

University of Maryland - Greenebaum Cancer Center, Baltimore

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

45242

Oncology Hematology Care, Cincinnati

48201

Karmanos Cancer Center, Detroit

64132

MidAmerica Division,Inc, Kansas City

66205

University of Kansas Cancer Center, Westwood

75231

Texas Oncology Presbyterian Cancer Center Dallas, Dallas

07652

The Valley Hospital, Paramus

Sponsors
All Listed Sponsors
lead

Marker Therapeutics, Inc.

INDUSTRY

NCT02593227 - Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter